Investment Rating - The report maintains an "Accumulate" investment rating for the company, considering its reasonable valuation and development prospects, with expected EPS of 2.38 and 3.00 yuan for 2024 and 2025 respectively, leading to PE ratios of 14.34 and 11.39 [2][10]. Core Insights - The company has achieved a revenue of 972 million yuan in 2023, representing a year-on-year growth of 13.87%. However, the net profit attributable to shareholders decreased by 22.65% to 153 million yuan [10][18]. - The company is focusing on diversifying its business layout, with significant progress in new products and projects, particularly in molecular sieve applications in energy, petrochemicals, and environmental governance [10][17]. - The company has successfully supplied molecular sieves for major projects, including the world's second-largest natural gas project, enhancing its market position [10][17]. Financial Performance Summary - The company reported a net profit of 198 million yuan in 2022, which decreased to 153 million yuan in 2023, with a projected recovery to 198 million yuan in 2024 [5][18]. - Operating cash flow is expected to improve significantly from -98 million yuan in 2023 to 247 million yuan in 2024, indicating a positive trend in cash generation [5][18]. - The company's revenue is projected to grow to 1.16 billion yuan in 2024, with a growth rate of 19.67% [18][21]. Business Development - The company is actively expanding its international market presence, with a notable increase in orders from Europe and Southeast Asia, particularly in the methane purification sector [17]. - New product sales in 2023 reached approximately 24 million yuan, with significant contributions from automotive brake systems and air suspension systems [10][17]. - The company is enhancing its R&D efforts to develop innovative products that address market needs, which is expected to drive future growth [10][17].
年报点评:分子筛业务表现稳健,业务结构优化构建长期增长动力